Better Therapeutics, Inc. (BTTX): Price and Financial Metrics
BTTX Price/Volume Stats
| Current price | $0.01 | 52-week high | $1.35 |
| Prev. close | $0.01 | 52-week low | $0.01 |
| Day low | $0.01 | Volume | 143,300 |
| Day high | $0.01 | Avg. volume | 4,974,345 |
| 50-day MA | $0.06 | Dividend yield | N/A |
| 200-day MA | $0.27 | Market Cap | 498.62K |
BTTX Stock Price Chart Interactive Chart >
Better Therapeutics, Inc. (BTTX) Company Bio
As of October 29, 2021, Mountain Crest Acquisition Corp. II was acquired by Better Therapeutics, Inc., in a reverse merger transaction. Mountain Crest Acquisition Corp. II. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or related business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.
Latest BTTX News From Around the Web
Below are the latest news stories about BETTER THERAPEUTICS INC that investors may wish to consider to help them evaluate BTTX as an investment opportunity.
Better Therapeutics Strengthens Financial Position Through Amendment to Debt Facility and Implementation of Cost ReductionsSAN FRANCISCO, November 28, 2023--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today disclosed several initiatives aimed at extending the company's cash runway sufficiently to demonstrate commercial traction with its lead product, AspyreRx. The company launched AspyreRx in October of this year, after receiving U.S. Food and Drug Administration (FDA) authorization in July for the treatment of adults w |
Frost & Sullivan Honors Better Therapeutics with the 2023 Technology Innovation Leadership AwardSAN FRANCISCO, November 14, 2023--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today announced it has been awarded Frost & Sullivan’s prestigious 2023 Best Practices Technology Innovation Leadership Award in the North American diabetes digital behavioral therapeutics industry. |
Better Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdatesSAN FRANCISCO, November 09, 2023--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics to treat cardiometabolic diseases, today reported financial results for the third quarter 2023 and provided an update on progress towards achieving key corporate milestones. |
Better Therapeutics to Release Third Quarter 2023 Financial Results and Provide Business Update on November 09, 2023SAN FRANCISCO, November 08, 2023--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics to treat cardiometabolic diseases, today announced it will release its third quarter 2023 financial results before the market opens on Thursday, November 09, 2023. Management will host a conference call and webcast to provide a business update at 8:30 a.m. ET / 5:30 a.m. PT on Thursday, November 09, 2023. |
Better Therapeutics to Participate in the American College of Lifestyle Medicine’s 2023 Annual ConferenceSAN FRANCISCO, October 26, 2023--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today announced its participation in the American College of Lifestyle Medicine's (ACLM) 2023 Lifestyle Medicine Annual Conference (LM2023), to be held October 29 to November 1, 2023, in Denver, Colorado. The conference brings together medical professionals, including physicians, healthcare executives, academic faculty, and |
BTTX Price Returns
| 1-mo | 1.01% |
| 3-mo | -94.87% |
| 6-mo | -93.33% |
| 1-year | -98.93% |
| 3-year | -99.90% |
| 5-year | N/A |
| YTD | -94.87% |
| 2023 | -82.35% |
| 2022 | -76.24% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...